ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,381.35
0.33%
Dow Jones
39,387.76
0.85%
Gold vs US Dollar
2,352.855
0.26%
Brent Oil
84.16
0.25%
Bitcoin
62,839.77
-0.33%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Cellectis SA (CLLS)

  7. Cellectis SA (CLLS) News

Cellectis (CLLS)

Cellectis SA
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CLLS
DateTimeSourceHeadlineSymbolCompany
06/05/202411:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CLLSCellectis SA
06/05/202407:00GlobeNewswire Inc.Cellectis Announces Completion of the Additional Equity Investment by AstraZenecaNASDAQ:CLLSCellectis SA
02/05/202421:30GlobeNewswire Inc.Cellectis Appoints Arthur Stril as Interim Chief Financial OfficerNASDAQ:CLLSCellectis SA
29/04/202421:46GlobeNewswire Inc.Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023NASDAQ:CLLSCellectis SA
22/04/202421:30GlobeNewswire Inc.Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCsNASDAQ:CLLSCellectis SA
10/04/202421:30GlobeNewswire Inc.Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCsNASDAQ:CLLSCellectis SA
08/04/202421:30GlobeNewswire Inc.Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual MeetingNASDAQ:CLLSCellectis SA
16/01/202421:45Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CLLSCellectis SA
16/01/202421:30GlobeNewswire Inc.Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)NASDAQ:CLLSCellectis SA
22/12/202321:35Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CLLSCellectis SA
22/12/202321:30GlobeNewswire Inc.Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023NASDAQ:CLLSCellectis SA
22/12/202321:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CLLSCellectis SA
05/12/202321:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CLLSCellectis SA
17/11/202321:56Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CLLSCellectis SA
17/11/202321:35Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CLLSCellectis SA
17/11/202321:30GlobeNewswire Inc.Cellectis’ Shareholders Meeting to be Held on December 22, 2023NASDAQ:CLLSCellectis SA
15/11/202312:48Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CLLSCellectis SA
15/11/202307:30GlobeNewswire Inc.Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZenecaNASDAQ:CLLSCellectis SA
09/11/202321:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CLLSCellectis SA
06/11/202321:35Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CLLSCellectis SA
06/11/202321:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CLLSCellectis SA
06/11/202321:30GlobeNewswire Inc.Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023NASDAQ:CLLSCellectis SA
02/11/202320:35Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CLLSCellectis SA
02/11/202320:30GlobeNewswire Inc.Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual MeetingNASDAQ:CLLSCellectis SA
01/11/202320:35Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CLLSCellectis SA
01/11/202320:35Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CLLSCellectis SA
01/11/202320:30GlobeNewswire Inc.Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023NASDAQ:CLLSCellectis SA
01/11/202319:15AllPennyStocks.comBiotech Shares Soar After AstraZeneca Stake & Research CollaborationNASDAQ:CLLSCellectis SA
01/11/202311:52Dow Jones NewsCellectis Shares Soar Premarket on AstraZeneca DealNASDAQ:CLLSCellectis SA
01/11/202311:51Dow Jones NewsCellectis Shares Soar Premarket on AstraZeneca DealNASDAQ:CLLSCellectis SA
 Showing the most relevant articles for your search:NASDAQ:CLLS

Your Recent History

LSE
ITM
Itm Power
LSE
AGL
Angle
LSE
SAR
Sareum
LSE
TYM
Tertiary Minerals
LSE
PEN
Pennant
LSE
EMG
Man
LSE
GKP
Gulf Keystone Petroleum
NYSE
SPCE
Virgin Galactic
LSE
GDP
Goldplat
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved